The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
Open accessAbstract
Background Angiogenesis is the process of neovascularization from pre-existing vasculature and is involved in various physiological and pathological processes. Inhibitors of angiogenesis, administered either as individual drugs or in combination with other chemotherapy, have been shown to benefit patients with various cancers. Endostatin, a 20-kDa C-terminal fragment of type XVIII collagen, is one of the most potent inhibitors of angiogenesis. Scope of review We discuss the biology behind endostatin in the context of its endogenous production, the various receptors to which it binds, and the mechanisms by which it acts. We focus on its inhibitory role in angiogenesis, lymphangiogenesis, and cancer metastasis. We also present emerging clinical applications for endostatin and its potential as a therapeutic agent in the form a short peptide. Major conclusions The delicate balance between pro- and anti-angiogenic factors can be modulated to result in physiological wound healing or pathological tumor metastasis. Research in the last decade has emphasized an emerging clinical potential for endostatin as a biomarker and as a therapeutic short peptide. Moreover, elevated or depressed endostatin levels in diseased states may help explain the pathophysiological mechanisms of the particular disease. General significance Endostatin was once sought after as the ‘be all and end all’ for cancer treatment; however, research throughout the last decade has made it apparent that endostatin’s effects are complex and involve multiple mechanisms. A better understanding of newly discovered mechanisms and clinical applications still has the potential to lead to future advances in the use of endostatin in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Soon after the discovery of endostatin’s critical role in inhibiting angiogenesis, the pharmaceutical development of endostatin became the focus of much research [229].”
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · cited 1×
“To date, 23 vertebrate members of the matrixin family, zinc-dependent proteases known to be involved in tissue remodeling and ECM degradation, have been identified [87].”
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Ricard-Blum, S. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004978 · Cited by 2,305
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Basement membrane proteoglycans: from cellar to ceiling
Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521
Matricryptins and matrikines: biologically active fragments of the extracellular matrix
Ricard‐Blum, S., & Salza, R. (2014) · Experimental Dermatology · doi:10.1111/exd.12435 · Cited by 224
Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro
Wick, N., Saharinen, P., Saharinen, J., Gurnhofer, E., Steiner, C. W., Raab, I., Stokic, D., Giovanoli, P., Buchsbaum, S., Burchard, A., et al. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00037.2006 · Cited by 106
Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models
Lee, C., Wu, C., & Shiau, A. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.626 · Cited by 93
Cited by
Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy
Gao, M., Yu, F., Lv, C., Choo, J., & Chen, L. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00908e · Cited by 827
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression
Brassart-Pasco, S., Brézillon, S., Brassart, B., Ramont, L., Oudart, J.-B., & Monboisse, J. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00397 · Cited by 335
The Functional Role of Extracellular Matrix Proteins in Cancer
Popova, N. V., & Jücker, M. (2022) · Cancers · doi:10.3390/cancers14010238 · Cited by 275
Macrophage-Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis
Zuo, T., Xie, Q., Liu, J., Yang, J., Shi, J., Kong, D., Wang, Y., Zhang, Z., Gao, H., Zeng, D.-B., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.039 · Cited by 70
Self-citationRole of hypohalous acids in basement membrane homeostasis
Colon, S., Page-McCaw, P., & Bhave, G. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7245 · Cited by 38
Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy
Wahnou, H., El Kebbaj, R., Hba, S., Ouadghiri, Z., El Faqer, O., Pinon, A., Liagre, B., Limami, Y., & Duval, R. E. (2025) · Cancers · doi:10.3390/cancers17071232 · Cited by 35
Metadata
- Authors
- Walia, A., Yang, J. F., Huang, Y.-H., Rosenblatt, M. I., Chang, J.-H., & Azar, D. T.
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 1850
- Issue
- 12
- Pages
- 2422-2438
- ISSN
- 0304-4165 (ISSN-L)
- OpenAlex
- W1879220818
- Cited by
- 182
- References
- 10
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.